LAMICTAL      ARIPIPRAZOLE      CARBAMAZEPINE      LITHIUM      OLANZAPINE      QUETIAPINE   
   RISPERIDONE      SSRI      TOPIRAMATE      VALPROATE      ZIPRASIDONE   
OLANZAPINE        USAGE 
Marketing information
Key claims
Reduced relapse rate
Longer time to relapse
At least as effective as lithium
OFC in bipolar depression
No treatment-emergent mania
Improvements in HR-Qol
Fewer drop-outs than lithium
No QTc prolongation
Usage
Country information
References
Supported by GSK.
(c) 2004 Excerpta Medica
All rights reserved.
Disclaimer
print this page
 Usage

Olanzapine has been prescribed to over 12.5 million patients worldwide.

GSK counterclaim:

Lamictal has been prescribed to over 5.5 million patients worldwide, with over 13 years experience.



  		  
home help sitemap acronyms help sitemap home